Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

Company Overview - Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel therapeutic targeting toxic soluble amyloid beta oligomers (AβOs) for Alzheimer's disease (AD) treatment [4] - The company is headquartered in Newton, Massachusetts and is advancing its investigational product candidate, sabirnetug (ACU193), in an ongoing Phase 2 clinical trial named ALTITUDE-AD [4] Upcoming Event - Acumen will host a virtual R&D Day on October 2, 2024, at 10:00 a.m. ET, to present its strategic vision and discuss the mechanistic rationale, pre-clinical, and clinical data supporting the development of sabirnetug for early AD [1] - The event will feature discussions from Acumen's management and scientific leadership, along with external key opinion leaders on the current treatment paradigm and unmet needs in early Alzheimer's disease [2] Clinical Development - Sabirnetug is a humanized monoclonal antibody that selectively targets toxic soluble AβOs and is currently in Phase 2 clinical trials after positive results in its Phase 1 trial, INTERCEPT-AD [4] - The ongoing Phase 2 ALTITUDE-AD trial is investigating sabirnetug in early symptomatic Alzheimer's disease patients [4]